JCR

JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion

Retrieved on: 
Tuesday, March 19, 2024
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, JCR, Therapy, Alexion, Related, Neurodegenerative disease

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) today announced that it has achieved the first research milestone criterion in a collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”) to develop an undisclosed initial therapeutic molecule that applies JCR’s proprietary J-Brain Cargo®, blood-brain barrier penetration technology, for the treatment of a neurodegenerative disease.

Key Points: 
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) today announced that it has achieved the first research milestone criterion in a collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”) to develop an undisclosed initial therapeutic molecule that applies JCR’s proprietary J-Brain Cargo®, blood-brain barrier penetration technology, for the treatment of a neurodegenerative disease.
  • The achievement of a predefined research milestone triggers a milestone payment to JCR.
  • JCR recently strengthened its collaboration with Alexion to address unmet needs by initiating a second research collaboration in December 2023 to apply the same technology to oligonucleotide therapeutics.
  • The milestone payment has a minor impact on JCR’s consolidated financial results for this fiscal year ending on March 31, 2024.

JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease Community

Retrieved on: 
Thursday, February 29, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, JCR, Anxiety, Caregiver, Physician, Dream, Quality of life, Hope, RDD, DSM-IV codes, Rare Disease Day, Disease, Internal, Pharmaceutical industry

RDD activities aim to raise awareness of rare diseases and to improve the quality of life of individuals with rare and intractable diseases through better diagnoses and treatments.

Key Points: 
  • RDD activities aim to raise awareness of rare diseases and to improve the quality of life of individuals with rare and intractable diseases through better diagnoses and treatments.
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) endorses the important mission of RDD and will advocate for RDD 2024 in Japan.
  • There are more than 6,000 rare diseases with an estimated 300 million individuals worldwide living with a rare disease.
  • Highlights of external awareness raising-activities for RDD:
    For JCR, RDD does not stop on the last day of February; it reminds us of our purpose every day to help raise awareness and generate change for the rare disease community worldwide.

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

Retrieved on: 
Wednesday, February 14, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Enzyme replacement therapy, BBB, JCR, MPS II, Traffic barrier, Glycogen storage disease, Ministry, MHLW, ERT, Hunter syndrome, Syndrome, Scheie syndrome, MPS, Safety, Developmental psychology, Hurler syndrome, Child, Patient, Hurler–Scheie syndrome, Trial of the century, Consciousness, DSM-IV codes, Hypotension, Mouse, Pharmaceutical industry

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) today announced the presentation of several datasets demonstrating the potential benefits of its investigational therapies for lysosomal storage disorders (LSDs).

Key Points: 
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) today announced the presentation of several datasets demonstrating the potential benefits of its investigational therapies for lysosomal storage disorders (LSDs).
  • JCR is dedicated to address the unmet medical needs for this community,” said Shin Ashida, President and CEO of JCR Pharmaceuticals.
  • Finally, the third JR-141 presentation is pre-clinical and highlights the recovery of retinal function in mice with MPS II.
  • “We are pleased to be able to offer IZCARGO® to patients with MPS II in Japan,” said Yoshikatsu Eto, M.D., Ph.D., Institute of Neurological Disorders, Advanced Clinical Research Center, Kanagawa, Japan.

JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024

Retrieved on: 
Thursday, January 25, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Hurler, Patient, Enzyme replacement therapy, PST, Hunter syndrome, MPS II, JCR, Eto, BBB, MPS, Medicine, MHLW, Ikeda, ERT, Syndrome, Safety, Traffic barrier, Glycogen storage disease, Scheie syndrome, Ministry, Pharmaceutical industry

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that it will present six presentations at the 20th Annual WORLDSymposium™ 2024, to be held February 4-9, 2024 in San Diego, Calif.

Key Points: 
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that it will present six presentations at the 20th Annual WORLDSymposium™ 2024, to be held February 4-9, 2024 in San Diego, Calif.
  • In addition to posters being available for each of the presentations, two of them will be shared as oral presentations given by a clinical investigator and a researcher from JCR Pharmaceuticals.
  • A global phase III study of pabinafusp alfa (JR-141) for neuronopathic mucopolysaccharidosis type II: updated study design (Ikeda, et al.)
  • WORLDSymposium™ attendees who would like to receive more information about JCR Pharmaceuticals can visit JCR’s on-site conference booth (#506) or visit its virtual booth on the WORLDSymposium™ conference website.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Ispire Technology Inc. - ISPR

Retrieved on: 
Friday, December 22, 2023
LLP, News, Pomerantz, JCR, Cryptocurrency

NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR).

Key Points: 
  • NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR).
  • The investigation concerns whether Ispire and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On November 30, 2023, J Capital Research (“JCR”) published a report on Ispire entitled “Insider Enrichment Scheme Where ~30% of Revenue May Be Fabricated”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Ispire Technology Inc. - ISPR

Retrieved on: 
Thursday, December 14, 2023
LLP, ISPR, News, Pomerantz, JCR, Cryptocurrency

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR).

Key Points: 
  • NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR).
  • The investigation concerns whether Ispire and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On November 30, 2023, J Capital Research (“JCR”) published a report on Ispire entitled “Insider Enrichment Scheme Where ~30% of Revenue May Be Fabricated”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Ispire Technology Inc. - ISPR

Retrieved on: 
Tuesday, December 5, 2023
LLP, ISPR, News, Pomerantz, JCR, Cryptocurrency

NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR).

Key Points: 
  • NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR).
  • The investigation concerns whether Ispire and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On November 30, 2023, J Capital Research (“JCR”) published a report on Ispire entitled “Insider Enrichment Scheme Where ~30% of Revenue May Be Fabricated”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration

Retrieved on: 
Thursday, December 21, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Research and development, Partnership, JCR, AAV, Brain, Glycogen storage disease, Medical device

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo® Technology.

Key Points: 
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo® Technology.
  • Under the agreement signed on March 28, 2022, JCR and Takeda collaborated on the research and development of AAV-mediated gene therapies that apply JCR’s J-Brain Cargo® technology.
  • The discontinuation is due to the change in Takeda's previously announced Research & Development (R&D) strategy to discontinue R&D on AAV-mediated gene therapy approaches.
  • “Through our collaboration, we secured proof-of-concept for a gene therapy using our proprietary J-Brain Cargo® technology platform,” said Shin Ashida, Chairman and President of JCR.

JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology

Retrieved on: 
Thursday, December 21, 2023
General Health, Health, Science, Other Science, Research, AstraZeneca, Antibody, BBB, Tissue, JCR, Neurodegenerative disease, Enzyme, Central nervous system, Alexion, Peptide, Therapy, Oligonucleotide, Pharmaceutical industry

Under the terms of the agreement, JCR and Alexion will research and develop oligonucleotide therapeutics using J-Brain Cargo® Technology.

Key Points: 
  • Under the terms of the agreement, JCR and Alexion will research and develop oligonucleotide therapeutics using J-Brain Cargo® Technology.
  • As part of the collaboration, Alexion may nominate up to three targets in rare disease indications for pre-clinical development using the platform.
  • Following pre-clinical development, Alexion will have the option to develop and commercialize the potential new drug candidates.
  • The collaboration is the second agreement between JCR and Alexion in 2023, following a March announcement regarding a research collaboration, option and license agreement to develop therapeutic protein candidates using J-Brain Cargo® for neurodegenerative disease.

U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

Retrieved on: 
Friday, December 15, 2023
FDA, Health, Science, Pharmaceutical, Research, Food, MPS, European Commission, ODD, Disease, Clinical trial, Civil service commission, Patient, BBB, JCR, NCT, TSE, ClinicalTrials.gov, Sanfilippo, Traffic barrier, Pharmaceutical industry

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (ODD) to JR-441, an investigational drug for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, or Sanfilippo syndrome type A).

Key Points: 
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (ODD) to JR-441, an investigational drug for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, or Sanfilippo syndrome type A).
  • JR-441 is a blood-brain barrier (BBB)-penetrating form of recombinant heparan N-sulfatase that was developed using JCR’s proprietary J-Brain Cargo® BBB-penetrating technology.
  • JCR is currently conducting a global Phase I/II clinical trial for JR-441, with the first patient with MPS IIIA dosed in October 2023.
  • We look forward to advancing JR-441 in clinical development and bringing this very important treatment to patients with MPS IIIA as quickly and safely as possible."